CHDI Foundation

Devices & Diagnostics

Medtronic’s research partnership: a roadmap to the future?

Last week, CHDI Foundation, a not-for-profit research organization, said it would "initially" pay up to 50 percent of clinical costs of a drug/device therapy being developed by Medtronic and Alnylam Pharmaceutical to treat Huntington's disease. While medical device and biopharmaceutical companies are partnering more and more, the inclusion of the foundation in this trio is what's interesting.

Devices & Diagnostics

Medtronic joins with drug company to treat Huntington’s disease

Medtronic Inc. (NYSE:MDT) said Wednesday it will form an alliance with a pharmaceutical firm and research foundation to develop a unique drug/device therapy to treat Huntington's disease. The medical firm, based in Fridley, Minnesota, said it will partner with Alnylam Pharmaceutical Inc. (Nasdaq:ALNY) and the CHDI Foundation to deliver a cutting-edge drug technology directly to the brain using an implantable infusion system being developed by Medtronic.

sponsored content

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.